NAMS
Price
$27.79
Change
-$0.67 (-2.35%)
Updated
Jul 31 closing price
Capitalization
3.25B
9 days until earnings call
Intraday BUY SELL Signals
ROIV
Price
$33.91
Change
-$0.61 (-1.77%)
Updated
Jul 31 closing price
Capitalization
24.5B
3 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NAMS vs ROIV

NAMS vs ROIV Comparison Chart in %
View a ticker or compare two or three
VS
NAMS vs. ROIV commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a Hold and ROIV is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (NAMS: $27.79 vs. ROIV: $33.91)
Brand notoriety: NAMS and ROIV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAMS: 63% vs. ROIV: 67%
Market capitalization -- NAMS: $3.25B vs. ROIV: $24.5B
NAMS [@Biotechnology] is valued at $3.25B. ROIV’s [@Biotechnology] market capitalization is $24.5B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAMS’s FA Score shows that 1 FA rating(s) are green whileROIV’s FA Score has 1 green FA rating(s).

  • NAMS’s FA Score: 1 green, 4 red.
  • ROIV’s FA Score: 1 green, 4 red.
According to our system of comparison, both NAMS and ROIV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAMS’s TA Score shows that 3 TA indicator(s) are bullish while ROIV’s TA Score has 3 bullish TA indicator(s).

  • NAMS’s TA Score: 3 bullish, 6 bearish.
  • ROIV’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ROIV is a better buy in the short-term than NAMS.

Price Growth

NAMS (@Biotechnology) experienced а -6.24% price change this week, while ROIV (@Biotechnology) price change was -3.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

Reported Earning Dates

NAMS is expected to report earnings on Aug 12, 2026.

ROIV is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ROIV($24.5B) has a higher market cap than NAMS($3.25B). ROIV YTD gains are higher at: 56.267 vs. NAMS (-20.781). NAMS has higher annual earnings (EBITDA): -214.95M vs. ROIV (-1.28B). ROIV has more cash in the bank: 4.29B vs. NAMS (636M). NAMS has less debt than ROIV: NAMS (23K) vs ROIV (107M). NAMS has higher revenues than ROIV: NAMS (22.6M) vs ROIV (8.26M).
NAMSROIVNAMS / ROIV
Capitalization3.25B24.5B13%
EBITDA-214.95M-1.28B17%
Gain YTD-20.78156.267-37%
P/E RatioN/A1.97-
Revenue22.6M8.26M274%
Total Cash636M4.29B15%
Total Debt23K107M0%
TECHNICAL ANALYSIS
Technical Analysis
NAMSROIV
RSI
ODDS (%)
Bearish Trend 4 days ago
68%
Bearish Trend 4 days ago
65%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bearish Trend 4 days ago
54%
Bearish Trend 4 days ago
79%
MACD
ODDS (%)
Bearish Trend 4 days ago
52%
Bearish Trend 4 days ago
66%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
64%
Bearish Trend 4 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
65%
Bearish Trend 4 days ago
73%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 6 days ago
77%
Bearish Trend 6 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
NAMS
Daily Signal:
Gain/Loss:
ROIV
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MRDN11.270.12
+1.03%
Meridian Holdings Inc.
BANF112.820.66
+0.59%
BancFirst Corp
SG6.45-0.10
-1.53%
Sweetgreen
MRM0.95-0.03
-3.06%
MEDIROM Healthcare Technologies
EIX73.37-5.36
-6.81%
Edison International

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with PTGX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-2.35%
PTGX - NAMS
42%
Loosely correlated
-1.44%
IMVT - NAMS
40%
Loosely correlated
-2.18%
ROIV - NAMS
39%
Loosely correlated
-1.77%
VKTX - NAMS
37%
Loosely correlated
-4.14%
PCVX - NAMS
37%
Loosely correlated
-3.36%
More